Chemomab Therapeutics Ltd.
For the period ended Nov 21, 2025. Filed Nov 21, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Nov 21, 2025 · Filed Nov 21, 2025
Use the contents to explore the available documents and sections.
Contents
EXPLANATORY NOTE
Chemomab Therapeutics Ltd. (the “Company”) hereby furnishes under this Report of Foreign Private Issuer on Form 6-K (the “Form 6-K”) the following: (i) press release, dated November 20, 2025, titled “Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Corporate Update” as Exhibit 99.1 to this Form 6-K.
Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into Company’s Registration Statements on Form F-3 (File No. 333-275002 and No. 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.